FENC
Fennec Pharmaceuticals, Inc.
NASDAQ · Healthcare · Biotechnology · US
$10.62
−1.48%Price chart
Aug 19Aug 24Aug 27Sep 1Sep 4Sep 10Sep 15Sep 18
Key dataSep 18, 2026
Open$10.68
From 52W high−16.90%
Volume126304.00
Market cap$372.41M
P/E (TTM)—
P/S (TTM)6.3x
Div yield—
Key dataSep 18, 2026
Open
$10.68
From 52W high
−16.90%
Volume
126304.00
Market cap
$372.41M
ValuationView details →
P/E (Fwd)
18.7x
EV/EBITDA
−139.4x
P/E (TTM)
—
RSI (14)
40.9
MomentumView details →
1D Return
−1.48%
YTD Return
+38.18%
SummaryUpdated Jun 1, 2026
Fennec Pharmaceuticals Inc. (NASDAQ:FENC) is a biopharmaceutical company founded in 1996 and headquartered in Research Triangle Park, North Carolina. Originally incorporated as Adherex Technologies Inc., the company changed its name to Fennec Pharmaceuticals in September 2014 to reflect its focused mission on pediatric oncology. The company went public in September 2017 and has since established itself as a specialized player in the rare disease pharmaceutical space, specifically targeting the prevention of chemotherapy-induced hearing loss in cancer patients.
Similar companies
Latest newsMore news →
Fennec Pharmaceuticals announced an oral presentation of detailed results from the investigator-initiated Phase 2 STS-J01 clinical study of Pedmark in Japan at SIOP 2026, with the primary endpoint met as ASHA-defined hearing loss occurred in 24.0% of patients versus the prespecified historical benchmark of 56.4% (P=0.001).3d agoAdherex Technologies, operating as Fennec Pharmaceuticals, reported second-quarter 2026 net product sales of $17.1 million, up approximately 78% from $9.7 million in the prior-year period.40d ago